Hypertension Canada’s 2016 Canadian Hypertension Education Program guidelines for pharmacists: An update

Canadian Pharmacists Journal

Volumn 149, Issue 6, 2016, Pages 337-344

  Al Hamarneh, Yazid N ^a,b   Houle, Sherilyn K D ^c   Padwal, Raj ^d   Tsuyuki, Ross T ^a,b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c UNIVERSITY OF WATERLOO   (Canada)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ATENOLOL; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; POTASSIUM; TRIACYLGLYCEROL; VERAPAMIL;

ACUTE CORONARY SYNDROME; ARTICLE; AWARENESS; BLOOD PRESSURE; BLOOD PRESSURE MONITORING; CANADA; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CONTROLLED CLINICAL TRIAL (TOPIC); DIABETES MELLITUS; EDUCATION PROGRAM; HEALTH BEHAVIOR; HEALTH CARE; HIGH RISK PATIENT; HUMAN; HYPERKALEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; MEDICATION COMPLIANCE; META ANALYSIS (TOPIC); MORTALITY; PATIENT HEALTH QUESTIONNAIRE; PHARMACIST; PRACTICE GUIDELINE; PREVALENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC);

EID: 84993972046     PISSN: 17151635     EISSN: 1913701X     Source Type: Journal    
DOI: 10.1177/1715163516671747     Document Type: Article

References (59)

1. Campbell NR, Burgess E, Choi BCK. Methods and overview of the Canadian recommendations. CMAJ 1999;160(9 suppl):S1-S6.
2. Leung AA, Nerenberg K, Daskalopoulou SS. Hypertension Canada’s 2016 Canadian Hypertension Education Program guidelines for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol 2016;32:569-88.
3. Joffers M, Falaschetti E, Gillespie C. Hypertension prevalence, awareness, treatment and control in national surveys from England, the USA and Canada, and correlation with stroke and ischaemic heart disease mortality: a cross-sectional study. BMJ Open 2013;3(8):e003423.
4. Padwal RS, Bienek A, McAlister FA, Campbell NR., Epidemiology of hypertension in Canada: an update. Can J Cardiol 2016;32:687-94.
5. Chisholm-Burns MA, Kim Lee J, Spivey CA. US pharmacists’ effect as a team member on patient care: systematic review and meta-analyses. Med Care 2010;48:923-33.
6. Santschi V, Chiolero A, Burnand A. Impact of pharmacist care in the management of cardiovascular disease risk factors: a systematic review and meta-analysis of randomized trials. Arch Intern Med 2011;171;1441-53.
7. Santschi V, Chiolero A, Paradis G. Pharmacist interventions to improve cardiovascular disease risk factors in diabetes: a systematic review and meta analysis of randomized controlled trials. Diabetes Care 2012;35:2706-17.
8. Santschi V, Chiolero A, Colosimo AL. Improving blood pressure control through pharmacist interventions: a meta-analysis of randomized controlled trials. J Am Heart Assoc 2014;3:e000718.
9. Tsuyuki R, Houle S, Charrois T. A randomized trial of the effect of pharmacist prescribing on improving blood pressure in the community: the Alberta clinical trial in optimizing hypertension (RxACTION). Circulation 2015;132:93-100.
10. Pojskic N, Jackson M, Malek A, Cimino S., Impact of community pharmacist interventions in hypertension management on patient outcomes: a randomized controlled trial. Can Pharm J (Ott) 2014;147:S17.
11. Tsuyuki RT, Al Hamarneh YN, Jones CA, Hemmelgarn BR., Effectiveness of community pharmacist prescribing and care on cardiovascular risk reduction: randomized controlled RxEACH trial. J Am Coll Cardiol 2016;67(24):2846-54. doi:10.1016/j.jacc.2016.03.528
12. Houle SKD, Tsuyuki RT, Campbell NRC. The Canadian Hypertension Education Program (CHEP) 2011 guidelines for pharmacists. Can Pharm J (Ott) 2011;144:295-304.
13. Houle SKD, Padwal R, Tsuyuki RT. The 2012-2013 Canadian Hypertension Education Program (CHEP) guidelines for pharmacists: an update. Can Pharm J (Ott) 2013;146:146-50.
14. Houle SKD, Padwal R, Poirier L, Tsuyuki RT. The 2014 Canadian Hypertension Education Program (CHEP) guidelines for pharmacists: an update. Can Pharm J (Ott) 2014;147:203-8.
15. Houle SKD, Padwal R, Poirier L, Tsuyuki RT. The 2015 Canadian Hypertension Education Program (CHEP) guidelines for pharmacists: an update. Can Pharm J (Ott) 2015;148:180-6.
16. Daskalopoulou SS, Rabi DM, Zarnke KB. The 2015 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol 2015;31:549-68.
17. Myers MG, Godwin M, Dawes M. Conventional versus automated measurement of blood pressure in primary care patients with systolic hypertension: randomised parallel design controlled trial. BMJ 2011;342:d286.
18. Myers MG, Valdivieso M, Kiss A., Consistent relationship between automated office blood pressure recorded in different settings. Blood Press Monit 2009;14:108-11.
19. Myers MG, Valdivieso M, Kiss A., Use of automated office blood pressure measurement to reduce the white coat response. J Hypertens 2009;27:280-6.
20. Wright JT, Jr Williamson JD, Whelton PK. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 2015;373:2103-16.
21. Brouwers MC, Kho ME, Browman GP. AGREE II: advancing guideline development, reporting and evaluation in health care. CMAJ 2010;182:E839-42.
22. Myers MG., A proposed algorithm for diagnosing hypertension using automated office blood pressure measurement. J Hypertens 2010;28:703-8.
23. Myers MG., The great myth of office blood pressure measurement. J Hypertens 2012;30:1894-8.
24. Myers MG., Eliminating the human factor in office blood pressure measurement. J Clin Hypertens (Greenwich) 2014;16:541-2.
25. Myers MG, Godwin M., Automated measurement of blood pressure in routine clinical practice. J Clin Hypertens (Greenwich) 2007;9:267-70.
26. Myers MG, Godwin M, Dawes M. Conventional versus automated measurement of blood pressure in the office (CAMBO) trial. Fam Pract 2012;29:376-82.
27. Greiver M, White D, Kaplan DM. Where should automated blood pressure measurements be taken? Pilot RCT of BpTRU measurements taken in private or nonprivate areas of a primary care office. Blood Press Monit 2012;17:137-8.
28. Myers MG, Godwin M, Dawes M. Measurement of blood pressure in the office: recognizing the problem and proposing the solution. Hypertension 2010;55:195-200.
29. Myers MG, Oh PI, Reeves RA, Joyner CD., Prevalence of white coat effect in treated hypertensive patients in the community. Am J Hypertens 1995;8:591-7.
30. Armstrong D, Matangi M, Brouillard D, Myers MG., Automated office blood pressure—being alone and not location is what matters most. Blood Press Monit 2015;20:204-8.
31. Padwal RS, Townsend RR, Trudeau L. Comparison of an in-pharmacy automated blood pressure kiosk to daytime ambulatory blood pressure in hypertensive subjects. J Am Soc Hypertens 2015;9:123-9.
32. Chambers LW, Kaczorowski J, O’Rielly S. Comparison of blood pressure measurements using an automated blood pressure device in community pharmacies and family physicians’ offices: a randomized controlled trial. CMAJ Open 2013;1:E37-42.
33. Andreadis EA, Agaliotis GD, Angelopoulos ET. Automated office blood pressure and 24-h ambulatory measurements are equally associated with left ventricular mass index. Am J Hypertens 2011;24:661-6.
34. Andreadis EA, Agaliotis GD, Angelopoulos ET. Automated office blood pressure is associated with urine albumin excretion in hypertensive subjects. Am J Hypertens 2012;25:969-73.
35. Campbell NR, McKay DW, Conradson H. Automated oscillometric blood pressure versus auscultatory blood pressure as a predictor of carotid intima-medial thickness in male firefighters. J Hum Hypertens 2007;21:588-90.
36. Myers MG, Kaczorowski J, Paterson JM. Thresholds for diagnosing hypertension based on automated office blood pressure measurements and cardiovascular risk. Hypertension 2015;66:489-95.
37. Sidhu D, Naugler C., Fasting time and lipid levels in a community-based population: a cross-sectional study. Arch Intern Med. 2012;172:1707-10.
38. Doran B, Guo Y, Xu J. Prognostic value of fasting versus nonfasting low-density lipoprotein cholesterol levels on long-term mortality: insight from the National Health and Nutrition Examination Survey III (NHANES-III). Circulation 2014;130:546-53.
39. Langsted A, Freiberg JJ, Nordestgaard BG., Fasting and nonfasting lipid levels: influence of normal food intake on lipids, lipoproteins, apolipoproteins, and cardiovascular risk prediction. Circulation 2008;118: 2047-56.
40. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group [erratum in Lancet 1999;354:602]. Lancet 1998;352:837-53.
41. Bansal S, Buring JE, Rifai N. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 2007;298:309-16.
42. Emerging Risk Factors Collaboration, Di Angelantonio E, Sarwar N. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009;302:1993-2000.
43. Nordestgaard BG, Varbo A., Triglycerides and cardiovascular disease. Lancet 2014;384:626-35.
44. Aldasouqi S, Sheikh A, Klosterman P. Hypoglycemia in patients with diabetes on antidiabetic medications who fast for laboratory tests. Diabetes Care 2011;34:e52.
45. de Vries M, Klop B, Castro Cabezas M. The use of the non-fasting lipid profile for lipid-lowering therapy in clinical practice—point of view. Atherosclerosis 2014;234:473-5.
46. Khera AV, Mora S., Fasting for lipid testing: is it worth the trouble? Arch Intern Med 2012;172:1710-2.
47. Aburto NJ, Hanson S, Gutierrez H. Effect of increased potassium intake on cardiovascular risk factors and disease: systematic review and meta-analyses. BMJ 2013;346:f1378.
48. Ettehad D, Emdin CA, Kiran J. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta analysis. Lancet 2016;387:957-67.
49. Xie X, Atkins E, Lv J. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet 2016;387:435-43.
50. Pepine CJ, Handberg EM, Cooper-DeHoff RM. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International VerapamilTrandolapril Study (INVEST): a randomized controlled trial. JAMA 2003;290:2805-16.
51. Dargie HJ, Ford I, Fox KM., Total Ischaemic Burden European Trial (TIBET). Effects of ischaemia and treatment with atenolol, nifedipine SR and their combination on outcome in patients with chronic stable angina. The TIBET Study Group. Eur Heart J 1996;17:104-12.
52. Rehnqvist N, Hjemdahl P, Billing E. Effects of metoprolol vs verapamil in patients with stable angina pectoris. The Angina Prognosis Study in Stockholm (APSIS). Eur Heart J 1996;17:76-81.
53. Andalib A, Akhtari S, Rigal R. Determinants of masked hypertension in hypertensive patients treated in a primary care setting. Intern Med J 2012;42:260-6.
54. Pickering TG, Davidson K, Gerin W, Schwartz JE., Masked hypertension. Hypertension 2002;40:795-796.
55. Ohkubo T, Kikuya M, Metoki H. Prognosis of “masked” hypertension and “white-coat” hypertension detected by 24-h ambulatory blood pressure monitoring 10-year follow-up from the Ohasama study. J Am Coll Cardiol 2005;46:508-15.
56. Grover SA, Lowensteyn I, Joseph L. Discussing coronary risk with patients to improve blood pressure treatment: secondary results from the CHECK-UP study. J Gen Intern Med 2009;24:33-9.
57. Gee ME, Bienek A, McAlister FA. Factors associated with lack of awareness and uncontrolled high blood pressure among Canadian adults with hypertension. Can J Cardiol 2012;28:375-82.
58. Stead LF, Hartmann-Boyce J, Perera R, Lancaster T., Telephone counselling for smoking cessation. Cochrane Database Syst Rev 2013:CD002850.
59. Cahill K, Lancaster T., Workplace interventions for smoking cessation. Cochrane Database Syst Rev 2014:CD003440.